Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
13 September 2019Website:
http://www.springworkstx.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 11 min agoDividend
Analysts recommendations
Institutional Ownership
Included in screeners
SWTX Latest News
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Securities Alec Stranahan - Bank of America Operator Good morning. My name is Tanya, and I will be your conference operator today.
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET.
– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter –
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment –
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN –
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference, taking place in Boston, Massachusetts on Wednesday, November 13, 2024 at 1:00 p.m. ET.
Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding in place to get the company to profitability in the years ahead.
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?
- 1(current)
- 2
What type of business is SpringWorks Therapeutics?
SpringWorks Therapeutics, Inc. is a biopharmaceutical company operating in the clinical stage. The company is focused on acquiring, developing, and commercializing medicines for patients suffering from rare diseases and oncological diseases. The company has a portfolio of oncology product candidates targeting small molecules, and other programs aimed at treating genetically defined types of cancer. It provides nirogacestat, which is an oral small molecule gamma-secretase inhibitor (GSI). It also provides mirdametinib, which is an oral low molecular weight MEK inhibitor. Mirdametinib is being developed for the treatment of plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN). SpringWorks Therapeutics, Inc. was founded in 2017, with its headquarters located in Stamford, Connecticut.
What sector is SpringWorks Therapeutics in?
SpringWorks Therapeutics is in the Healthcare sector
What industry is SpringWorks Therapeutics in?
SpringWorks Therapeutics is in the Biotechnology industry
What country is SpringWorks Therapeutics from?
SpringWorks Therapeutics is headquartered in United States
When did SpringWorks Therapeutics go public?
SpringWorks Therapeutics initial public offering (IPO) was on 13 September 2019
What is SpringWorks Therapeutics website?
https://www.springworkstx.com
Is SpringWorks Therapeutics in the S&P 500?
No, SpringWorks Therapeutics is not included in the S&P 500 index
Is SpringWorks Therapeutics in the NASDAQ 100?
No, SpringWorks Therapeutics is not included in the NASDAQ 100 index
Is SpringWorks Therapeutics in the Dow Jones?
No, SpringWorks Therapeutics is not included in the Dow Jones index
When was SpringWorks Therapeutics the previous earnings report?
No data
When does SpringWorks Therapeutics earnings report?
The next expected earnings date for SpringWorks Therapeutics is 27 February 2025